Page 1

HOOKIPA PHARMA HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent Highlights May 12 , 2021 • Oncology programs advance with preliminary Phase 1 immunogenicity data showing robust antigen - specific CD8 + T cell response after one dose of HB - 201 or HB - 202 ; clinical results consistent with those observed in pre - clinical studies • HOOKIPA on track to report additional HB - 201 and HB - 202 clinical data on T cell response and preliminary antitumor activity at ASCO and other upcoming conferences NEW YORK and VIENNA , Austria , May 12 , 2021 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ : HOOK , ' HOOKIPA ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform , today reported financial results and business highlights for the first quarter of 2021 . " We had a strong start to the year as we drive our pipeline forward to deliver a new class of arenavirus - based immunotherapeutics . As we shared at AACR , one initial dose of our lead oncology candidates , HB - 201 or HB - 202 , each induced a robust increase in antigen - specific T cells , including an increase of up to 8 % of antigen - specific circulating CD8 + T cells , in people with advanced Human Papillomavirus 16 - positive ( HPV16 + ) cancers , " said Joern Aldag , Chief Executive Officer at HOOKIPA . " We believe these data are impressive , and they are consistent with the pre - clinical data published in Cell Reports Medicine in March . Both data sets highlight the potential of our engineered arenavirus platform to redefine success in cancer immunotherapy . As our clinical programs progress , we're excited about the oral abstract presentation at ASCO ( # 2502 ) and other future data presentations at upcoming conferences . " Program Highlights • In April 2021 , HOOKIPA announced positive preliminary Phase 1 immunogenicity data for its lead oncology candidates , HB - 201 and HB - 202 , for the treatment of advanced HPV16 + cancers , reinforcing the promising anti - tumor activity reported from the Phase 1/2 clinical trial in December 2020. The preliminary immunogenicity data demonstrated a robust increase in HPV16 + -specific T cells , including an increase of up to 8 % of antigen - specific circulating CD8 + T cells , after one dose of HB - 201 or HB - 202 . Early HB - 201 monotherapy data also highlighted immune system activation of increasing interferon - gamma and other immune stimulatory cytokines with a single dose . The data were presented at a late - breaker poster session at the virtual American Association for Cancer Research ( AACR ) Annual Meeting . • In March , Cell Reports Medicine published pre - clinical data on HOOKIPA's arenaviral therapeutics . The peer - reviewed article showed that intravenous HB - 201 administration induced single digit percentage of antigen - specific CD8 + T cells , while alternating administration of HB - 201 and HB - 202 induced a potent CD8 + T cell response , exceeded 50 % of the circulating T cell pool . The two - vector cancer therapeutic approach also resulted in tumor cures and long - term immunity in a pre - clinical setting . • HOOKIPA's prophylactic Cytomegalovirus , or CMV , vaccine candidate , HB - 101 , continued to enroll patients awaiting kidney transplantation in a Phase 2 clinical trial . We expect to conclude trial enrollment in mid - 2021 and to report additional safety , immunogenicity , and efficacy data from evaluable patients in the second half of 2021 . Upcoming Milestones • Oral abstract presentation at ASCO ( # 2502 at 3:00 pm EDT on June 7 ) : First report of the safety / tolerability and preliminary antitumor activity of HB - 201 and HB - 202 , an arenavirus - based cancer immunotherapy , in patients with HPV16 + cancers • Initial HB - 201 / HB - 202 Phase 1/2 efficacy data in HPV16 + cancers in mid - 2021 • Additional HB - 101 CMV Phase 2 efficacy data in H2 2021 • Advancing our HB - 300 to IND for the treatment of metastatic prostate cancer • HBV HIV collaboration Gilead Sciences advancing towards clinical studies First Quarter 2021 Financial Results Cash Position : HOOKIPA's cash , cash equivalents and restricted cash as of March 31 , 2021 was $ 128.1 million compared to $ 143.2 million as of December 31 , 2020. The decrease was primarily attributable to cash used in operating activities . Revenue was $ 5.3 million for the three months ended March 31 , 2021 , and $ 3.7 million for the three months ended March 31 , 2020. The increase was primarily due to higher cost reimbursements received under the Collaboration Agreement with Gilead and the recognition of cost reimbursements initially recognized as deferred revenue .